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Abstract
Several fluorinated derivatives of the anti-HIV maturation agent bevirimat (1) were synthesized 
and evaluated for anti-HIV replication activity. The modified positions were the C-2, C-3, C-28, 
and C-30 positions, either directly on the betulinic acid (2) skeleton or in the attached side chains. 
Compound 18, which has a trifluoromethyl group added to C-30 of its isopropenyl group, 
exhibited similar potency to 1 against HIV-1NL4-3. In total, our current studies support our prior 
conclusion that C-30 allylic modification is unlikely to be a pharmacophore for anti-HIV activity, 
but could be a meaningful route to manipulate other properties of 2-related compounds.
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HIV-1 infection affects more than 30 million people worldwide, and its treatment remains a 
serious problem due to the emergence of drug-resistant HIV strains and deleterious side 
effects. Thus, the discovery and development of new drug candidates with novel anti HIV 
mechanisms remain important to solve the problems of this disease.
Bevirimat (DSB, 1 in Fig. 1), a triterpene natural product derivative, represents a promising 
class of anti-HIV agents with a novel mechanism. It inhibits HIV-1 maturation by blocking 
the cleavage of p25 to functional p24, resulting in the production of noninfectious HIV-1 
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particles. In recent years, efforts to improve the anti-HIV activity of 1 have focused on 
modifications at the C-3 and C-28 positions, particularly, insertion of side chains containing 
various functional groups, such as anhydrides, amino acids, and N-heterocycles.1 
Correspondingly, success was achieved by the synthesis of new compounds with better 
EC50 data than 1 itself. However, improving the anti-HIV potency is not necessarily the sole 
driving force for modification of 1. For instance, structural changes can help define 
pharmacophores related to biological profile as well as potency. Also, the possibility of 
creating a new lead compound with action at a different HIV process/enzyme is always 
significant and meaningful in the field of anti-HIV research. Consequently, alteration of the 
activity or biological profile of a preclinical drug candidate can often be regarded as an 
important strategy in drug design.
Fluorinated drugs and drug candidates based on natural products are present in many 
therapeutic classes. Fluorine has unique physical properties, such as strong electronegativity, 
small atomic size, and low polarizability of the C—F bond, and can mimic either a hydrogen 
or hydroxy group.2–7 A recent literature review extensively discussed fluorine’s effects on 
conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and 
pharmacokinetic properties, concluding that its incorporation into a molecule can be 
significantly important in medicinal chemistry and the design of valuable future drugs.8 
Thus, the introduction of one or more fluorine atoms into the structure of 1 could 
dramatically influence the lipophilicity, conformational flexibility, metabolic stability, or 
other properties, which could be useful in modulating the biological activity or 
pharmaceutical profile of 1. With this consideration in mind, herein, we report the synthesis 
of fluorinated derivatives of 1 and evaluation of their anti-HIV activities.
Readily modifiable positions of the betulinic acid (BA, 2) scaffold include the C-2, C-3, 
C-28, and C-19 positions. We introduced fluorine atoms either directly at C-2 or C-3 as 
shown in Scheme 1 or indirectly in the C-29, or C-3 and C-28 side chains of 2 as shown in 
Schemes 2 and 3 (see Supplementary data for the detailed synthetic procedures). Therefore, 
we could evaluate the effects of fluorine atoms in several different positions.
Firstly, as shown in Scheme 1, the CO2H group of betulinic acid (3) was protected with 
CH3I to obtain the ester 4. Then, compound 4 was treated with lithium diisopropylamide 
(LDA) and N-fluorobenzenesulfonimide (NFSI) at −78 °C, resulting in the introduction of 
one fluorine atom at the C-2 α-position (5) in 43% yield. Similarly, if the CO2H group was 
esterified with 2-cyclopropyl ethanol, one fluorine atom was also introduced easily from the 
α-face at the C-2 position at −78 °C. In addition, when 4 was treated with CF3Si(CH3)3, a 
CF3 functional group was inserted at the C-3 position (12). Furthermore, application of 
classical organic synthetic methods including reduction by NaBH4, esterification with 2,2-
dimethylsuccinic anhydride, or removal of a methyl ester with LiI, the desired fluorinated 
products 8, 9, 11, and 13 were obtained.
Secondly, the fluorinated modification of the isopropenyl group on C-19 is shown as 
Scheme 2. Betulin (14) was protected as its diacetate 15. Then, a CF3 group was added at 
the C-30 position in 25% yield by treating 15 with S-(trifluoromethyl)diarylsulfonium salt 
using copper thiophenecarboxylate (CuTC) as catalyst to produce the fluorinated key 
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intermediate 16. The desired product 18 was obtained in a four-step sequence, deprotection 
of 16 with 2 N NaOH in THF/EtOH, oxidization with CrO3/H2SO4, reduction with NaBH4, 
and finally, esterification with 2,2-dimethylsuccinic anhydride.
Thirdly, fluorine atoms were introduced at various positions in the side chains on the BA 
C-3 and C-28 positions as shown in Scheme 3. Compounds 21 and 22, in which the C-28 
side chain terminates in a trifluoromethylphenyl and difluorocyclohexyl group, respectively, 
were synthesized easily via esterification of 3 with 3-(trifluoromethyl)phenethyl alcohol or 
4,4-difluorocyclohexane methanol, respectively. Fluorine atoms were incorporated in the 
C-3 side chain by esterifying 2 directly with tetrafluorosuccinic or hexafluoroglutaric 
anhydride to provide 23 and 24, respectively.
All of the synthesized new fluorinated compounds (8, 9, 11, 13, 18, 21–24) were evaluated 
for anti HIV activity by determining inhibition of NL4-3 virus replication in MT4 
lymphocytes.9 Table 1 shows the anti-HIV results for the tested compounds, with the lead 
compound 1 as a positive control.
With one exception, the fluorinated compounds were much less active than the non-
fluorinated lead compound 1. Five compounds (8, 9, 13, 23, and 24) did not show anti-HIV 
potency at the highest concentration tested. Indeed, the inactivity of 9, which differs 
structurally from 1 only by a fluorine rather than hydrogen at C-2, might suggest that a 
proton at C-2 could play a critical role for anti HIV activity. The importance of the 
dimethylsuccinyl C-3 ester group to the anti-HIV activity was confirmed by the inactivity of 
the fluorinated esters 23 and 24. Two compounds with fluorine in the C-28 ester side chain 
showed only weak anti-HIV activity with (4,4-difluorocyclohexyl)methyl (22) resulting in 
greater potency than trifluoromethylphenethyl (21). However, compounds 1 and 18, which 
has a trifluoromethyl group added to C-30 of the isopropenyl group of 1, exhibited similar 
potency against HIV-1NL4-3. Based on the data, this position was the only one among those 
tested to actually tolerate the addition of a fluorine atom. This finding was not unexpected, 
because prior studies had shown that certain changes in the isopropenyl group (e.g., 
saturation of the 20(29) double bond,10 thioether,11 or oxyether12 substitution at C-30) did 
not appreciably impact the anti-HIV-1 potency of derivatives of 2. Thus, our studies confirm 
the previous conclusion that C-30 allylic modification is unlikely to be a pharmacophore for 
anti-HIV activity, but could be a meaningful route to manipulate other properties of 2-
related compounds.12
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Figure 1. 
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Scheme 1. 
Reagents and conditions: (a) CH3I, K2CO3, DMF, 40 °C; (b) LDA, NFSI, THF, −78 °C–rt; 
(c) NaBH4, EtOH/THF, rt; (d) 2,2-dimethylsuccinic anhydride, DMAP, pyridine, 120 °C; 
(e) LiI, DMF, 140 °C; (f) CF3Si(CH3)3, Bu4N+F−, THF, rt; then 6 M HCl; (g) (CO)2Cl2, 
CH2Cl2, rt; then 2-cyclopropylethanol, Et3N, CH2Cl2, rt.
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Scheme 2. 
Reagents and conditions: (h) Ac2O, pyridine, CH2Cl2, rt; (i) S-
(trifluoromethyl)diarylsulfonium salt, CuTc, 2,4,6-collidine, DMA, 40 °C; (j) 2 N NaOH, 
THF/EtOH, rt; (k) CrO3/H2SO4, acetone, 0–5 °C.
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Scheme 3. 
Reagents and conditions: (l) (CO)2Cl2, CH2Cl2, rt; then 3-(trifluoromethyl)phenethyl 
alcohol, Et3N, CH2Cl2, rt; (m) (CO)2Cl2, CH2Cl2, rt; then 4,4-difluorocyclohexane 
methanol, Et3N, CH2Cl2, rt; (n) tetrafluorosuccinic anhydride, CH2Cl2, 0 °C–rt; (o) 
hexafluoroglutaric anhydride, CH2Cl2, 0 °C–rt.
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Table 1
Anti-HIV data for fluorinated target compounds
Compd EC50 (μM) NL4–3 # of tests CC50 (μM) MT4
8 >16 4 >16
9 >17 4 >17
11 1.1 ± 0.28 3 >6
13 >6 3 >6
18 0.097 ± 0.025 3 >6
21 3.0 ± 0.49 3 >5
22 0.31 ± 0.067 3 >6
23 >6 1 >6
24 >6 1 >6
1 (Bevirmat, DSB) 0.075 ± 0.0155 4 >17
Note: For compounds 8 and 9, the highest concentration tested was 17 μM (10 μg/mL). For the remaining compounds 11, 13, 18, and 21–24, the 
highest concentration tested was 6 μM (4 μg/mL).
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